Skip to main content Skip to main navigation menu Skip to site footer

Evaluation of prostate cancer on MRI with PI-RADS 2.1: A serial case


Background: Cancer that affects men's prostate glands is called prostate cancer. Magnetic resonance imaging (MRI) is a much more recommended method of examination because it evaluates the prostate in detail. MRI with Prostate Imaging–Reporting and Data System (PI-RADS) 2.1 can be used as a reporting system for prostate expertise and looking at the character of a lesion. This case series aims to present the prostate cancer cases on MRI with PI-RADS 2.1.

Case report: First case, a 61-year-old male patient came with complaints of bloody urine and difficulty urinating. MRI results showed a well-defined lesion at the apex to mid of the peripheral zone in the right and left posteromedial sector, without extraprostatic extension, according to PI-RADS 4, and a lesion with indistinct boundaries at the apex, mid to base of the transition zone, with extraprostatic extension to the bladder, according to PI-RADS 5. The second case, a man aged 63 years with complaints of difficulty urinating and feeling incomplete for 1 month. The MRI results suggested prostatic hypertrophy with intravesical protrusion of +/- 1.2 cm with an ill-defined lesion in the mid portion of the right and left posterolateral peripheral zone, suggesting PI-RADS 4 and an ill-defined lesion at the left anterior transitional zone apex, suggesting PI-RADS 3. In the third case, a 79-year-old man came with complaints of discomfort when urinating. The MRI showed lesions with ill-defined borders on the posterior aspect of the mid-inferior portion of the right peripheral zone according to PI-RADS 5, and multiple lesions with ill-defined borders on the anteroposterior segment of the apex-inferior portion transitional zone correspond to PI-RADS 5.

Conclusion: MRI with PI-RADS 2.1 can evaluate suspected malignancy in the prostate, so it can be considered as the modality of choice in evaluating malignancy in the prostate.


  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
  2. Hernandez J, Thompson IM. Diagnosis and treatment of prostate cancer. Med Clin North Am. 2004;88(2):267–79, ix.
  3. Baldisserotto M, Neto EJD, Carvalhal G, de Toledo AF, de Almeida CM, Cairoli CED, et al. Validation of PI-RADS v.2 for prostate cancer diagnosis with MRI at 3T using an external phased-array coil. J Magn Reson Imaging. 2016;44(5):1354–9.
  4. Heidenreich A, Abrahamsson P-A, Artibani W, Catto J, Montorsi F, Van Poppel H, et al. Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol. 2013;64(3):347–54.
  5. Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76(3):340–51.
  6. Fabijańska A. A novel approach for quantification of time-intensity curves in a DCE-MRI image series with an application to prostate cancer. Comput Biol Med. 2016;73:119–30.
  7. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2021;79(2):263–82.
  8. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–22.
  9. Haas M, Günzel K, Penzkofer T, Maxeiner A, Fischer T, Miller K, et al. [Implications of PI-RADS Version 1 and Updated Version 2 on the Scoring of Prostatic Lesions in Multiparametric MRI]. Aktuelle Urol. 2016;47(5):383–7.
  10. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. 2020;77(1):38–52.

How to Cite

Winata, H. S., & Patriawan, P. (2024). Evaluation of prostate cancer on MRI with PI-RADS 2.1: A serial case. Intisari Sains Medis, 15(1), 501–505.




Search Panel

Herry Sofyan Winata
Google Scholar
ISM Journal

Putu Patriawan
Google Scholar
ISM Journal